US12622891B2 - AMP-activated protein kinase activator - Google Patents

AMP-activated protein kinase activator

Info

Publication number
US12622891B2
US12622891B2 US18/566,730 US202218566730A US12622891B2 US 12622891 B2 US12622891 B2 US 12622891B2 US 202218566730 A US202218566730 A US 202218566730A US 12622891 B2 US12622891 B2 US 12622891B2
Authority
US
United States
Prior art keywords
compound
group
mmol
mixture
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US18/566,730
Other languages
English (en)
Other versions
US20240277657A1 (en
Inventor
Susumu Nakata
Naoto Kojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto Pharmaceutical University
Original Assignee
Kyoto Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Pharmaceutical University filed Critical Kyoto Pharmaceutical University
Assigned to KYOTO PHARMACEUTICAL UNIVERSITY reassignment KYOTO PHARMACEUTICAL UNIVERSITY ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: NAKATA, SUSUMU, KOJIMA, NAOTO
Publication of US20240277657A1 publication Critical patent/US20240277657A1/en
Application granted granted Critical
Publication of US12622891B2 publication Critical patent/US12622891B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US18/566,730 2021-06-04 2022-06-03 AMP-activated protein kinase activator Active 2043-06-09 US12622891B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-094481 2021-06-04
JP2021094481 2021-06-04
PCT/JP2022/023390 WO2022255499A1 (ja) 2021-06-04 2022-06-03 新規なamp活性化プロテインキナーゼ活性化剤

Publications (2)

Publication Number Publication Date
US20240277657A1 US20240277657A1 (en) 2024-08-22
US12622891B2 true US12622891B2 (en) 2026-05-12

Family

ID=84322602

Family Applications (1)

Application Number Title Priority Date Filing Date
US18/566,730 Active 2043-06-09 US12622891B2 (en) 2021-06-04 2022-06-03 AMP-activated protein kinase activator

Country Status (5)

Country Link
US (1) US12622891B2 (cg-RX-API-DMAC7.html)
EP (1) EP4349331A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022255499A1 (cg-RX-API-DMAC7.html)
CN (1) CN117794527A (cg-RX-API-DMAC7.html)
WO (1) WO2022255499A1 (cg-RX-API-DMAC7.html)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040162317A1 (en) 2003-02-06 2004-08-19 Georg Fertig Mono-acylated o-phenylendiamines derivatives
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2006062224A1 (ja) 2004-12-07 2006-06-15 Takeda Pharmaceutical Company Limited カルボキサミド誘導体
WO2006088921A2 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
US20070037888A1 (en) 2003-10-17 2007-02-15 Astrazeneca Ab 4-(Pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
JP2008504285A (ja) 2004-06-23 2008-02-14 バイエル・フアーマシユーチカルズ・コーポレーシヨン ガン化学療法薬として有用な2−アミノアリールカルボキシアミド
JP2011178728A (ja) 2010-03-02 2011-09-15 Kobe Univ Ampk活性化剤、glut4活性化剤、およびそれらを用いた医薬品・飲食品
WO2011162267A1 (ja) 2010-06-22 2011-12-29 株式会社 三和化学研究所 新規チオフェンカルボキサミド誘導体及びその医薬用途
US20130345243A1 (en) 2011-03-07 2013-12-26 Glaxosmithkline Llc 1h-pyrollo[3,2-d]pyrimidinedione derivatives
WO2014069426A1 (ja) 2012-10-31 2014-05-08 塩野義製薬株式会社 Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体
WO2014204895A1 (en) 2013-06-18 2014-12-24 Albert Einstein College Of Medicine Of Yeshiva University Treatment of obesity and pulmonary arterial hypertension
WO2018174078A1 (ja) 2017-03-21 2018-09-27 富士フイルム株式会社 ペプチド化合物およびその製造方法、スクリーニング用組成物、並びにペプチド化合物の選択方法
JP2020083811A (ja) 2018-11-22 2020-06-04 国立大学法人 鹿児島大学 1,5−アンヒドロフルクトース誘導体を含むampk活性化剤
US20200339742A1 (en) * 2019-04-29 2020-10-29 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Breathable Elastomeric Composites with Tether-Containing Conducting Polymers for Nanoscale Diffusion Control and Protection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043366A2 (en) 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
JP7131034B2 (ja) 2018-03-30 2022-09-06 株式会社三洋物産 遊技機

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501451B2 (en) 2003-02-06 2009-03-10 Hoffmann-La Roche Inc. Mono-acylated o-phenylendiamines derivatives
US20060089403A1 (en) 2003-02-06 2006-04-27 Georg Fertig Mono-acylated o-phenylendiamines derivatives
US7071219B2 (en) 2003-02-06 2006-07-04 Hoffmann-La Roche Inc. Mono-acylated o-phenylendiamines derivatives
JP2006516553A (ja) 2003-02-06 2006-07-06 エフ.ホフマン−ラ ロシュ アーゲー 新規なモノ−アシル化o−フェニレンジアミン誘導体
US20040162317A1 (en) 2003-02-06 2004-08-19 Georg Fertig Mono-acylated o-phenylendiamines derivatives
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20070037888A1 (en) 2003-10-17 2007-02-15 Astrazeneca Ab 4-(Pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
US7579349B2 (en) 2003-10-17 2009-08-25 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
JP2007510626A (ja) 2003-10-17 2007-04-26 アストラゼネカ アクチボラグ 癌の治療に使用の4−(ピラゾール−3−イルアミノ)ピリミジン誘導体
JP2008504285A (ja) 2004-06-23 2008-02-14 バイエル・フアーマシユーチカルズ・コーポレーシヨン ガン化学療法薬として有用な2−アミノアリールカルボキシアミド
US20080293696A1 (en) 2004-06-23 2008-11-27 Bayer Pharmaceuticals Corporation 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents
WO2006062224A1 (ja) 2004-12-07 2006-06-15 Takeda Pharmaceutical Company Limited カルボキサミド誘導体
US7868005B2 (en) 2005-02-16 2011-01-11 Schering Corporation Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
US20070054919A1 (en) 2005-02-16 2007-03-08 Schering Corporation Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
WO2006088921A2 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
JP2011178728A (ja) 2010-03-02 2011-09-15 Kobe Univ Ampk活性化剤、glut4活性化剤、およびそれらを用いた医薬品・飲食品
WO2011162267A1 (ja) 2010-06-22 2011-12-29 株式会社 三和化学研究所 新規チオフェンカルボキサミド誘導体及びその医薬用途
US20130345243A1 (en) 2011-03-07 2013-12-26 Glaxosmithkline Llc 1h-pyrollo[3,2-d]pyrimidinedione derivatives
JP2014507453A (ja) 2011-03-07 2014-03-27 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 1H−ピロロ[3,2−d]ピリミジンジオン誘導体
WO2014069426A1 (ja) 2012-10-31 2014-05-08 塩野義製薬株式会社 Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体
WO2014204895A1 (en) 2013-06-18 2014-12-24 Albert Einstein College Of Medicine Of Yeshiva University Treatment of obesity and pulmonary arterial hypertension
US20160113933A1 (en) 2013-06-18 2016-04-28 Albert Einstein College Of Medicine, Inc. Treatment of obesity and pulmonary arterial hypertension
US9603852B2 (en) 2013-06-18 2017-03-28 Albert Einstein College Of Medicine, Inc. Treatment of obesity and pulmonary arterial hypertension
WO2018174078A1 (ja) 2017-03-21 2018-09-27 富士フイルム株式会社 ペプチド化合物およびその製造方法、スクリーニング用組成物、並びにペプチド化合物の選択方法
US20200040039A1 (en) 2017-03-21 2020-02-06 Fujifilm Corporation Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound
US11319347B2 (en) 2017-03-21 2022-05-03 Fujifilm Corporation Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound
JP2020083811A (ja) 2018-11-22 2020-06-04 国立大学法人 鹿児島大学 1,5−アンヒドロフルクトース誘導体を含むampk活性化剤
US20200339742A1 (en) * 2019-04-29 2020-10-29 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Breathable Elastomeric Composites with Tether-Containing Conducting Polymers for Nanoscale Diffusion Control and Protection

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
Extended European Search Report dated May 14, 2025 in European Patent Application No. 22816244.2.
International Application No. PCT/JP2022/023390, International Preliminary Report on Patentability, mailed May 29, 2023.
Kim et al., AMPK activators: mechanisms of action and physiological activities, Experim. Mol. Med., 48:e224 (2016).
Martin et al., An Elastomeric Poly(Thiophene-EDOT) Composite with a Dynamically Variable Permeability Towards Organic and Water Vapors, Adv. Func. Mat., 22(15):3116-3127 (2012).
Motoshima et al., AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer, J. Physiol., 574(Pt 1):63-71 (2006).
O'Neiii, AMPK and Exercise: Glucose Uptake and Insulin Sensitivity, Diab. Metab. J., 7(1):1-21 (2013).
Pilkington-Miksa, et al., "Design, synthesis, and biological evaluation of novel cRGD-Paclitaxel conjugates for integrin-assisted drug delivery", Bioconjugate Chemistry, vol. 23, No. 8, pp. 1610-1622 (2012).
Ruderman et al., AMPK, insulin resistance, and the metabolic syndrome, J. Clin. Invest., 123(7):2764-2772 (2013).
Extended European Search Report dated May 14, 2025 in European Patent Application No. 22816244.2.
International Application No. PCT/JP2022/023390, International Preliminary Report on Patentability, mailed May 29, 2023.
Kim et al., AMPK activators: mechanisms of action and physiological activities, Experim. Mol. Med., 48:e224 (2016).
Martin et al., An Elastomeric Poly(Thiophene-EDOT) Composite with a Dynamically Variable Permeability Towards Organic and Water Vapors, Adv. Func. Mat., 22(15):3116-3127 (2012).
Motoshima et al., AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer, J. Physiol., 574(Pt 1):63-71 (2006).
O'Neiii, AMPK and Exercise: Glucose Uptake and Insulin Sensitivity, Diab. Metab. J., 7(1):1-21 (2013).
Pilkington-Miksa, et al., "Design, synthesis, and biological evaluation of novel cRGD-Paclitaxel conjugates for integrin-assisted drug delivery", Bioconjugate Chemistry, vol. 23, No. 8, pp. 1610-1622 (2012).
Ruderman et al., AMPK, insulin resistance, and the metabolic syndrome, J. Clin. Invest., 123(7):2764-2772 (2013).

Also Published As

Publication number Publication date
EP4349331A4 (en) 2025-06-11
JPWO2022255499A1 (cg-RX-API-DMAC7.html) 2022-12-08
WO2022255499A1 (ja) 2022-12-08
CN117794527A (zh) 2024-03-29
EP4349331A1 (en) 2024-04-10
US20240277657A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
ES2981114T3 (es) 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios
CN112707900B (zh) 蛋白降解剂及其在疾病治疗中的应用
RU2667060C2 (ru) Производные маннозы для лечения бактериальных инфекций
JP6174117B2 (ja) 抗炎症活性でコンジュゲートされた増強された抗インフルエンザ剤
ES2732311T3 (es) Compuestos de manósidos y procedimientos de uso de los mismos
US20220169628A1 (en) Therapeutic agents and methods of treatment
EP1813614B1 (en) Cytotoxic agents comprising new tomaymycin derivatives
KR20210107046A (ko) 거대고리 화합물 및 질환 치료에서 이들의 용도
US20110166128A1 (en) Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
US20110166194A1 (en) Asenapine Prodrugs
KR101837488B1 (ko) 광학적으로 순수한 벤질-4-클로로페닐-c-글루코사이드 유도체
EA021196B1 (ru) Ингибиторы вирусов flaviviridae
US12552757B2 (en) NRF2-activating compound
AU2014248717B2 (en) Mannose derivatives for treating bacterial infections
US10072006B2 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
US20250195475A1 (en) Cdk2 inhibitor and preparation method and use thereof
JP2022521453A (ja) 複素環式の誘導体
US20250179055A1 (en) Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof
CA3100333A1 (en) Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
CA2946833A1 (en) Pyrrolopyrimidine compounds for prevention of tumors based on nae inhibitory effect
CN108403698A (zh) 用于治疗细菌感染的方法和组合物
US20240277657A1 (en) Novel amp-activated protein kinase activator
CN112118891B (zh) 作为流感病毒复制抑制剂的稠和多环吡啶酮化合物
US20180086760A1 (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
CN112533917B (zh) 作为vps34的抑制剂的吗啉衍生物

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: KYOTO PHARMACEUTICAL UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKATA, SUSUMU;KOJIMA, NAOTO;SIGNING DATES FROM 20231220 TO 20231222;REEL/FRAME:066275/0793

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE